Dyadic Applied BioSolutions, a global biotechnology company, has secured milestone payments in its collaborations with Proliant Health & Biologicals and Inzymes ApS for its animal-free proteins and enzymes. In the food and nutrition sector, Dyadic is working on developing non-animal human alpha-lactalbumin for infant nutrition, with sampling underway and licensing discussions in progress. Additionally, the company received a milestone payment from Inzymes for productivity improvements in non-animal dairy enzymes, with one enzyme set to launch soon.

In the life sciences sector, Dyadic achieved a productivity milestone in recombinant human albumin development through its partnership with Proliant. The company is also advancing lab-grade non-animal transferrin products and has validated the use of its DNase I in molecular biology, diagnostics, and biopharma applications. With a focus on commercialization and revenue growth, Dyadic continues to make progress in its partnerships and product development, poised for success in various markets.